Cargando…
Precision medicine: The future of diagnostic approach to pulmonary hypertension?
Pulmonary hypertension (PH) is a common finding that can result from many different pathological conditions. Depending on the etiology, treatment may be quite different, but early diagnosis and correct classification of PH is difficult. With an aging population and recently suggested decreased pulmo...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kare Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955078/ https://www.ncbi.nlm.nih.gov/pubmed/31584446 http://dx.doi.org/10.14744/AnatolJCardiol.2019.97820 |
_version_ | 1783486886303498240 |
---|---|
author | Kedzierski, Piotr Torbicki, Adam |
author_facet | Kedzierski, Piotr Torbicki, Adam |
author_sort | Kedzierski, Piotr |
collection | PubMed |
description | Pulmonary hypertension (PH) is a common finding that can result from many different pathological conditions. Depending on the etiology, treatment may be quite different, but early diagnosis and correct classification of PH is difficult. With an aging population and recently suggested decreased pulmonary arterial pressure threshold defining PH, we are facing even more diagnostic uncertainties. A new approach to patients’ phenotyping is needed. Here we present available data and future perspectives on employing an in-depth analysis of the omics cascade to allow an earlier and more reliable diagnosis and classification of PH. Indeed, with the help of super-fast computing, it became possible to simultaneously consider the levels of thousands of potential biomarkers to find patterns specific for clinically suspected disease. The omics cascade is an invaluable source of information. However, while the genome can be perceived as providing possibilities, transcriptome–as carving them this is metabolome that may tell us “what is really going on” in an individual living organism. Metabolomics research requires blinded search for characteristic patterns of discreet changes in the levels of detectable metabolites. Since as many as 40,000 various substances are produced as a “side effect of staying alive”, metabolite profiling can be compared to fishing up for organized signals in a universe of chaos. Although difficult, such search for metabolic patterns that might lead to replacing the term biomarker by metabolic fingerprinting in the area of pulmonary circulation has already begun. |
format | Online Article Text |
id | pubmed-6955078 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Kare Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-69550782020-01-16 Precision medicine: The future of diagnostic approach to pulmonary hypertension? Kedzierski, Piotr Torbicki, Adam Anatol J Cardiol Review Pulmonary hypertension (PH) is a common finding that can result from many different pathological conditions. Depending on the etiology, treatment may be quite different, but early diagnosis and correct classification of PH is difficult. With an aging population and recently suggested decreased pulmonary arterial pressure threshold defining PH, we are facing even more diagnostic uncertainties. A new approach to patients’ phenotyping is needed. Here we present available data and future perspectives on employing an in-depth analysis of the omics cascade to allow an earlier and more reliable diagnosis and classification of PH. Indeed, with the help of super-fast computing, it became possible to simultaneously consider the levels of thousands of potential biomarkers to find patterns specific for clinically suspected disease. The omics cascade is an invaluable source of information. However, while the genome can be perceived as providing possibilities, transcriptome–as carving them this is metabolome that may tell us “what is really going on” in an individual living organism. Metabolomics research requires blinded search for characteristic patterns of discreet changes in the levels of detectable metabolites. Since as many as 40,000 various substances are produced as a “side effect of staying alive”, metabolite profiling can be compared to fishing up for organized signals in a universe of chaos. Although difficult, such search for metabolic patterns that might lead to replacing the term biomarker by metabolic fingerprinting in the area of pulmonary circulation has already begun. Kare Publishing 2019 2019-09-25 /pmc/articles/PMC6955078/ /pubmed/31584446 http://dx.doi.org/10.14744/AnatolJCardiol.2019.97820 Text en Copyright: © 2019 Turkish Society of Cardiology http://creativecommons.org/licenses/by-nc-sa/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License |
spellingShingle | Review Kedzierski, Piotr Torbicki, Adam Precision medicine: The future of diagnostic approach to pulmonary hypertension? |
title | Precision medicine: The future of diagnostic approach to pulmonary hypertension? |
title_full | Precision medicine: The future of diagnostic approach to pulmonary hypertension? |
title_fullStr | Precision medicine: The future of diagnostic approach to pulmonary hypertension? |
title_full_unstemmed | Precision medicine: The future of diagnostic approach to pulmonary hypertension? |
title_short | Precision medicine: The future of diagnostic approach to pulmonary hypertension? |
title_sort | precision medicine: the future of diagnostic approach to pulmonary hypertension? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955078/ https://www.ncbi.nlm.nih.gov/pubmed/31584446 http://dx.doi.org/10.14744/AnatolJCardiol.2019.97820 |
work_keys_str_mv | AT kedzierskipiotr precisionmedicinethefutureofdiagnosticapproachtopulmonaryhypertension AT torbickiadam precisionmedicinethefutureofdiagnosticapproachtopulmonaryhypertension |